Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Totality Outcome of Afatinib Sequential Treatment in Patients With EGFR Sensitizing Mutation-positive NSCLC in South Korea

NCT04930133 is registered in ClinicalTrials.gov with Seoul St. Mary's Hospital as lead sponsor.

NCT NCT04930133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04930133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Totality Outcome of Afatinib Sequential Treatment in Patients With EGFR Sensitizing Mutation-positive NSCLC in South Korea
Lead sponsor
Seoul St. Mary's Hospital
Phase
Observational
Overall status
Unknown status
Start date
February 24, 2020
Completion date
September 30, 2021
Enrollment
737 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc